Review Article
DOI: https://doi.org/10.70749/ijbr.v3i5.1225

INDUS JOURNAL OF BIOSCIENCE RESEARCH
https://induspublishers.com/IJBR
ISSN: 2960-2793/ 2960-2807

Leveraging Artificial Intelligence in Pharmacy and Clinical Pharmacy Transformative Innovations for Precision, Operational Efficiency, and Enhanced Patient-Centered Care

Laiba Asif[1], Muhammad Danyal Khan[2], Maheen Rafique[3], Abdul Sami Shaikh[4], Farwa Iman[1], Misbah Mubeen[5], Ayesha Javaid[6], Gullelala Jadoon[7], Maha Zulfiqar[8], Mehwish Shaikh[9]

[1]Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University Lahore, Punjab, Pakistan.
[2]Faculty of Engineering Sciences & Technology, Iqra University, Karachi, Sindh, Pakistan.
[3]Department of Pharmacology, CMH Lahore Medical College and Institute of Dentistry Lahore, Punjab, Pakistan.
[4]Department of Computing Monarch, Institute of International Studies, Pakistan.
[5]Department of Chemistry, University of Agriculture, Faisalabad, Punjab, Pakistan.
[6]Department of Biochemistry, University of Layyah, Punjab, Pakistan.
[7]Department of Information Technology, University of Haripur, KP, Pakistan.
[8]Department of Biotechnology, Superior University Lahore, Punjab, Pakistan.
[9]Department of Software Engineering, Mehran University of Engineering and Technology, Jamshoro, Sindh, Pakistan.

ARTICLE INFO

Keywords: Drug Interaction Prediction, Healthcare Automation, Pharmacy Informatics, Patient-centered Care, AI in Drug Safety, Pharmacogenomics, Digital Health, Smart Drug Dispensing, Remote Patient Monitoring, Artificial Intelligence, Clinical Pharmacy, Precision Medicine, Machine Learning, Deep Learning, Drug Discovery, Personalized Medicine.

Correspondence to: Laiba Asif,
Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University, Lahore, Punjab, Pakistan.
Email: laibaasif112233@gmail.com

Declaration
Authors' Contribution: All authors equally contributed to the study and approved the final manuscript.
Conflict of Interest: No conflict of interest.
Funding: No funding received by the authors.

Article History
Received: 04-01-2025, Revised: 12-04-2025
Accepted: 21-04-2025, Published: 05-05-2025

ABSTRACT

By improving accuracy, operational effectiveness, and patient-centered care, the use of artificial intelligence (AI) in clinical pharmacy and pharmacy is transforming healthcare. Drug discovery, customized medicine, and pharmaceutical treatment management are being optimized by AI-driven advances, including machine learning algorithms, natural language processing, and predictive analytics. AI-powered decision support systems in clinical pharmacies increase workflow efficiency, decrease adverse medication reactions, and improve prescription accuracy. Real-time patient monitoring, AI-assisted drug use evaluations, and automated dispensing robots all help to optimize resources and enhance therapeutic results. Additionally, AI improves drug adherence through digital health interventions such as chatbots, virtual assistants, and smartphone apps that offer instructional help and customized reminders. Drug safety surveillance is strengthened by the early detection of adverse drug responses made possible by the incorporation of AI in pharmacovigilance. Despite these developments, competent AI implementation requires addressing issues including data protection, legal compliance, and ethical considerations. This paper examines how artificial intelligence (AI) is changing pharmacy and clinical pharmacy, highlighting significant advancements, advantages, and difficulties, as well as how it might change the way healthcare is delivered. Pharmacists may adopt a more proactive, data-driven strategy by utilizing AI, which will eventually enhance patient safety, treatment results, and healthcare efficiency. To enable AI's responsible and successful incorporation into pharmacy practice, future research should concentrate on improving AI algorithms, encouraging multidisciplinary cooperation, and creating strong regulatory frameworks. To satisfy the changing needs of precision medicine and patient-centric healthcare, this study emphasizes the critical necessity for ongoing developments in AI-driven pharmacy solutions.

Graphical Abstract



INTRODUCTION

A major paradigm change in healthcare is being brought about by the integration of artificial intelligence (AI) in pharmacy, which is transforming clinical decision-making, customized medicine, and drug discovery (Tade et al., 2024). By evaluating enormous datasets, forecasting molecular interactions, and discovering possible drug candidates at a never-before-seen speed, AI-driven algorithms are speeding up drug development and drastically cutting down on the time and expense involved in conventional pharmaceutical research. By customizing medications according to a patient's genetic profile, lifestyle choices, and illness development, machine learning models are also revolutionizing personalized medicine and guaranteeing more accurate and potent treatments. By moving away from a one-size-fits-all strategy and toward customized treatment plans, therapeutic results are improved while side effects are reduced (Hamdy et al., 2024). AI-powered solutions support pharmacists and medical professionals in clinical decision-making by examining patient histories, identifying possible drug interactions, and suggesting the best course of treatment. Even more sophisticated AI systems can monitor patient data in real-time, allowing for proactive interventions and a decrease in drug mistakes. Additionally, pharmacy processes are being streamlined by AI-powered automation, which ensures efficiency and lowers human error in tasks like predictive inventory management and robotic dispensing. AI's position in pharmacy is predicted to grow as it develops further, opening the door for more intelligent, data-driven strategies that improve patient care, increase medication efficacy, and reshape pharmaceutical research (Bhatt et al., 2024).

The switch from rule-based automation to self-learning AI in pharmacy signifies a major improvement in patient-centered treatment, accuracy, and efficiency (Badr et al., 2024). To handle duties like prescription dispensing, inventory control, and medication interaction checks, traditional rule-based automation in pharmacies depended on preset algorithms and stringent standards. Although this method reduced human error and increased operational efficiency, it was not flexible and needed constant human supervision for updates and changes. However, pharmaceutical systems are getting smarter, more predictive, and more customized with the introduction of self-learning AI. More precisely than static rule-based systems, machine learning algorithms can now evaluate enormous volumes of patient data, medication histories, and real-time health factors to suggest the best course of action and identify any negative drug interactions (Johnson et al., 2016). Real-time drug monitoring, automated medication reconciliation, and even chatbot-assisted patient consultations are made possible by AI-powered technologies like natural language processing (NLP) and deep learning models. Additionally, by speeding up drug discovery through molecular modeling, predictive analytics, and AI-driven clinical trials, self-learning AI is transforming pharmaceutical research and medication development. AI-driven robots in hospitals and retail pharmacies are improving the accuracy of medicine delivery while lightening the burden for pharmacists, freeing them up to concentrate on patient counseling and clinical decision-making. In addition to increasing workflow efficiency, the transition from strict automation to adaptive, self-improving AI also increases therapeutic results and pharmaceutical safety. Pharmacists' roles might be redefined by AI as technology develops, moving them from traditional dispensers to data-driven healthcare consultants that use AI for proactive patient care, individualized therapies, and precision medicine (Aungst et al., 2025).

Unprecedented breakthroughs in drug research, tailored medicine, and pharmaceutical care are being driven by AI-powered technologies that are transforming clinical pharmacy and drug discovery (Kandhare et al., 2025). AI-driven drug development is one of the most revolutionary fields; machine learning algorithms examine enormous biological datasets to find possible drug candidates more quickly and accurately than with conventional techniques. These algorithms are capable of optimizing drug formulations, forecasting molecular interactions, and even repurposing current drugs for novel therapeutic uses. AI-enhanced clinical decision support systems (CDSS) are another significant advance. These systems combine genetic data, patient data, and empirical evidence to help pharmacists make accurate, evidence-based recommendations for managing pharmaceutical therapy. By anticipating adverse medication responses, spotting possible drug-drug interactions, and guaranteeing the best possible dosage regimens, these technologies improve patient safety. Robotics and automation driven by AI are also increasing quality control, decreasing mistakes, and simplifying pharmaceutical manufacturing. Deep learning models and AI-driven virtual screening are also speeding up the discovery of biomolecular targets, which drastically cuts down on the time and expense involved in medication development (Bettanti et al., 2024). Additionally, enormous volumes of clinical trial data, patient records, and medical literature are being analyzed using natural language processing (NLP) to produce insights that researchers and pharmacists may use. By offering real-time, tailored advice, chatbots and virtual assistants driven by AI are revolutionizing patient counseling and medication adherence. It is anticipated that as AI develops further, its application in clinical pharmacy and drug discovery will improve precision medicine, maximize therapeutic results, and hasten the creation of next-generation therapies, all of which will eventually improve patient care and public health. This paper examines how artificial intelligence (AI) is revolutionizing pharmacy and clinical pharmacy, emphasizing how it affects patient-centered care, operational effectiveness, and precision medicine. To evaluate the effects of AI-driven advancements in pharmacy automation, tailored therapy, and drug discovery on clinical judgment, workflow efficiency, and better patient outcomes (Yadav et al., 2024).

Algorithmic Pharmacists
AI-Generated Drug Experts

The rise of "Algorithmic Pharmacists" signifies a revolutionary change in contemporary medicine, since AI is actively co-prescribing drugs with human physicians in addition to assisting them (Brett et al., 2018). These cutting-edge AI models are revolutionizing therapeutic decision-making, particularly in the context of polypharmacy, which is the simultaneous prescription of multiple medications for complex or chronic conditions. They were trained on extensive pharmacological databases, electronic health records, genomic profiles, and real-time patient data. The ability of these AI systems to quickly analyze multidrug interactions, identify potentially hazardous combinations, and optimize dosages based on patient-specific factors like age, comorbidities, and organ function makes polypharmacy risk assessment one of their most innovative uses (Barlow et al., 2021). Algorithmic pharmacists are already being included in decision-support systems in clinical settings to issue alarms. A new age of customized pharmacokinetics is also being ushered in by the development of next-generation AI technologies that use dynamic biological data, including wearable biometrics, microbiome profiles, and liver enzyme activity, to forecast individual drug metabolism in real-time. By taking this leap, doctors may make preemptive prescription adjustments that minimize adverse effects and maximize therapeutic results. A future of safer, quicker, and more individualized pharmaceutical treatment is promised by the partnership of human knowledge and machine intelligence as these technologies advance; in this scenario, the pharmacist's position will be reinvented through the lens of algorithmic accuracy rather than displaced (Allam et al., 2025).

Smart Implants & AI-Driven Drug Release Mechanisms

Therapeutic delivery is transforming thanks to the combination of biomedical engineering and artificial intelligence (AI), especially with the introduction of smart implants and AI-driven medication release systems (Ekpan et al., 2024). The creation of AI-powered nanobots that can carry out highly targeted medicine delivery at the cellular level is a noteworthy advancement in this field. To minimize systemic adverse effects and maximize treatment success, these nanoscale agents may be taught to explore complicated biological settings, recognize sick cells using AI-trained pattern recognition, and release therapeutic molecules precisely where required. In addition to nanobots, smart implants that have AI-controlled microdosing capabilities are revolutionizing the treatment of chronic illnesses by providing ongoing, individualized care. These implants use micro-dosing algorithms to modify medication administration in response to real-time physiological parameter monitoring, such as glucose levels, inflammatory markers, or brain activity. This ensures appropriate therapeutic doses while preventing overdose or underdosing (Rosendo et al., 2024). AI-driven bioresponsive medication systems that react dynamically to biological cues like pH shifts, hormone fluctuations, or temperature changes provide a complement to these developments. Based on real-time biometric inputs, these systems use machine learning models that have been trained on big datasets to forecast when and how much of a medicine should be released. When taken as a whole, these technologies represent a paradigm change in pharmacotherapy, opening the door for self-regulating, intelligent systems that provide hitherto unheard-of levels of accuracy, responsiveness, and customization in healthcare (Baxter et al., 2006).

AI & Psychedelic Pharmacotherapy
The Future of Mental Health Drugs

A new age of precision psychiatry is being promised by the combination of psychedelic pharmacology and artificial intelligence (AI), which is transforming the field of mental health care (Sarris et al., 2024). AI-enhanced psychedelic-assisted therapy is becoming a potent therapeutic strategy that customizes hallucinogenic treatment regimens to each patient's unique neurobiological profile, especially for depression and PTSD. Clinicians may now tailor dose, session scheduling, and therapy context to maximize therapeutic outcomes and minimize side effects using machine learning algorithms based on neuroimaging, genetic, and behavioral data. Additionally, the development of next-generation hallucinogenic drugs with enhanced selectivity and safety characteristics is heavily reliant on AI. Researchers are discovering new chemical structures that can precisely alter particular brain circuits linked to emotional and trauma-related diseases by employing generative models and neural network-based simulations. In addition to speeding up drug development, this method makes it possible to adjust psychoactive effects to better suit intended therapeutic goals, such as improving emotional processing or encouraging neuroplasticity (Cramer et al., 2011). The long-term cognitive and psychological effects of these drugs are also being clarified by AI-driven longitudinal research, which provides predictive insights into possible hazards, including memory or lasting perceptual abnormalities. AI systems can predict recovery, relapse, and cognitive evolution paths by combining real-world data from clinical trials and patient-reported results. This enables proactive intervention techniques. AI and psychedelic pharmacology have the potential to revolutionize our understanding and treatment of complicated mental health disorders as they continue to develop in tandem (Gonzalez-Rodriguez et al., 2023).

Synthetic Biology & AI Reprogramming Pharmacology

A paradigm change in pharmacology is being sparked by the intersection of synthetic biology and artificial intelligence (AI), namely in the areas of drug design, metabolization, and production (Bhatia et al., 2024). AI-driven enzyme engineering, which makes it possible to modify drug-metabolizing enzymes according to a person's genetic and metabolic profile, is among the most revolutionary uses. Researchers can now anticipate enzyme-substrate interactions with previously unheard-of accuracy by combining omics data with sophisticated machine learning algorithms. This allows for a genuinely ultra-personalized approach to therapeutic effectiveness optimization and side effect minimization. Digital twins, virtual, AI-powered copies of living cells that mimic drug activity at the molecular level, have emerged to complement this breakthrough (Mariam et al., 2024). Before beginning lab or clinical trials, researchers may test millions of pharmacological scenarios in silico using these computerized models, which lowers costs and speeds up the drug development process. Additionally, the building of microbial factories using synthetic biology and AI is transforming pharmaceutical production. Decentralized and on-site medication manufacture is a feasible future option thanks to genetically engineered bacteria and yeast that can be trained to biosynthesize complex therapies on demand according to AI-optimized metabolic pathways. In addition to pushing the limits of pharmacology, this combination of biological design and computer intelligence is establishing the foundation for a new age of patient-specific, effective, and responsive therapies (Marques et al., 2024).

Table 1

AI-Driven Innovations in Synthetic Biology for Reprogramming Pharmacology

Technology/ Approach	Description	AI Contribution	Pharmacological Impact	Key Challenges	Future Directions
AI-Driven Enzyme Engineering Deep mutational scanning & protein structure prediction (e.g., AlphaFold, RoseTTAFold)	High-throughput mutagenesis combined with AI to design enzymes tailored for specific drug metabolism profiles.	Predicts enzyme-substrate specificity; optimizes catalytic efficiency and substrate selectivity using generative models.	Enables ultra-personalized drug metabolism based on patient genotypes and gut microbiota profiles.	Predictive inaccuracies in real biological systems; limited clinical validation.	Integration with pharmacogenomic databases for real-time personalization.
Directed evolution with reinforcement learning	Iterative optimization of enzyme variants guided by machine learning fitness scoring.	RL algorithms evaluate the performance of enzyme variants and suggest mutations for desired properties.	Accelerates enzyme evolution cycles, reducing lab time from years to weeks.	Need for large training datasets; biosafety concerns.	Development of hybrid wet-lab/AI automation loops.
Multi-omics integration platforms	Combines genomics, transcriptomics, proteomics to train AI models on metabolic pathways.	AI mines patterns to predict optimal enzyme expressions and post-translational modifications.	Supports rational enzyme design for multi-drug regimens.	Data heterogeneity and integration complexity.	Standardized ontologies for omics-AI interfacing.
Digital Twins of Cells Virtual cellular avatars for simulating drug interactions	Cell-level simulation platforms trained on patient-specific omics data.	AI models simulate molecular dynamics, predict toxicities and off-target effects before clinical trials.	Reduces drug failure rates; supports in silico clinical testing.	High computational costs; biological complexity limitations.	Quantum-AI hybrids for large-scale dynamic modeling.
Neural network-based systems biology simulators	Deep learning frameworks that learn dynamic signaling pathway behaviors.	Captures emergent phenomena such as gene-drug-environment interactions.	Enables adaptive pharmacokinetics and pharmacodynamics (PK/PD) modeling.	Generalizability to diverse cell types remains a challenge.	Incorporation of real-time biosensor data for continuous model updates.
Incorporation of real-time biosensor data for continuous model updates. AI-integrated CRISPR libraries	CRISPR perturbations used to validate in silico predictions in physical models.	AI prioritizes experimental conditions and gene targets based on simulation outcomes.	Validates the safety and efficacy of drugs across cellular diversity.	Ethical and safety concerns with gene editing.	Synthetic twin repositories for public-access benchmarking.

for digital twin validation					
AI-Enhanced Microbial Biofactories AI-designed synthetic circuits in bacteria and yeast	AI constructs and optimizes genetic circuits for controlled biosynthesis of pharmaceuticals.	Predicts optimal promoter/enhancer combinations, metabolic loads, and chassis designs.	Facilitates scalable, cost-effective, and eco-friendly drug production.	Stability of circuits under variable environmental conditions.	Adaptive circuit designs with feedback learning.
AI-guided metabolic engineering of *E. coli*, *S. cerevisiae*	Modifies microbial pathways to synthesize complex drug molecules (e.g., insulin, artemisinin).	Models flux balance and optimizes yield and purity in real time.	Decentralizes pharmaceutical manufacturing (e.g., local drug printers).	Risk of horizontal gene transfer and contamination.	Regulation frameworks for AI-microbe safety assurance.
Swarm AI-controlled bioreactor systems	Networks of AI-controlled reactors dynamically adapt growth and synthesis parameters.	AI learns optimal fermentation conditions using reinforcement learning and digital twin feedback.	Increases yield efficiency; supports continuous, demand-based production.	Interfacing real-time control with biofeedback loops.	Cloud-connected, globally distributed micro-bioreactor grids.

AI-Powered CRISPR Drug Synthesis Redefining Precision Medicine

Through the smooth integration of gene-editing technology and computational intelligence, AI-powered CRISPR drug manufacturing is transforming precision medicine (Dixit et al., 2024). By orchestrating the intricate symphony of genome engineering, artificial intelligence plays the role of the "CRISPR maestro," enabling highly customized treatment plans based on each patient's unique genetic profile. AI makes it possible to identify the best CRISPR targets with previously unheard-of precision by using sophisticated algorithms and deep learning models. This guarantees that gene-editing initiatives are not only accurate but also in line with patient-specific mutations and disease pathways. Target validation, or the ability to identify therapeutic hotspots and verify them as effective intervention areas by evaluating large multi-omics datasets, is one of AI's most revolutionary functions in this field. This greatly speeds up the development of incredibly accurate gene therapy medications that can mute or fix defective genes with the fewest possible side effects (Friedmann et al., 197). Additionally, long before a CRISPR treatment is tested in clinical settings, AI models can accurately estimate and forecast off-target consequences, cutting down on trial-and-error cycles and improving safety profiles. The ethical use of gene-editing medicines and regulatory compliance depend on these predicted insights. AI is changing how scientists negotiate the complexities of CRISPR-based drug creation by acting as a digital compass, ultimately expanding the realm of what is feasible in genome-guided, customized medicine (Hemati et al., 2024).

Figure 1
AI-Powered CRISPR Drug Synthesis (Redefining Precision Medicine)



AI in Biopharmaceuticals & Protein-Based Drug Development

Biopharmaceuticals and protein-based medication research are undergoing fast change due to artificial intelligence (AI), which is propelling breakthroughs that have the potential to revolutionize current medicine (Prajapati et al., 2024). AI-simulated protein folding models, like DeepMind's AlphaFold, are among the most revolutionary developments. They have greatly improved our capacity to accurately forecast complicated protein structures. By offering insights on protein function, interaction sites, and therapeutic potential, all crucial for creating highly focused medications, this capacity speeds up the design of next-generation biopharmaceuticals. Additionally, AI is transforming vaccine production by simulating host-pathogen interactions using immune response prediction models, which allow researchers to improve adjuvant formulations and antigen selection for increased immunogenicity and effectiveness. When it comes to treating new infectious illnesses and customized vaccination plans, this predictive ability is very helpful. Furthermore, new antibody-drug conjugates (ADCs) and immune checkpoint inhibitors with enhanced selectivity and decreased toxicity are being created using generative AI models (Sobhani et al., 2024). Large chemical and biological regions may be explored by these AI-driven systems, producing optimal molecular candidates that conventional approaches would miss. AI is bringing in a new era of personalized medicine in biopharmaceuticals by combining deep learning, reinforcement learning, and multi-omics data. This is not only speeding up the drug discovery process but also making it possible to create precision biologics that are customized to each patient's unique profile (Ginsburg et al., 2001).

Neuromorphic AI for Drug Discovery Mimicking the Human Brain

Inspired by the structure and operations of the human brain, neuromorphic AI is quickly transforming the drug discovery field by providing a paradigm shift toward intelligent, adaptable, and real-time systems (Kumar et al., 2025). Neuromorphic systems mimic synaptic plasticity and parallel neural processing, which allows them to replicate human cognitive pathways like learning, pattern recognition, and decision-making, essential processes in the intricate field of pharmacological research, in contrast to traditional AI models that rely on linear computations and preset algorithms. Because they integrate dynamic, multidimensional biological input and refine molecular predictions through repeated self-learning cycles, these brain-inspired structures hold special promise for improving medication design. Incorporating quantum-inspired neuromorphic frameworks is particularly intriguing as it improves processing speed and accuracy and makes it possible to predict pharmacokinetics in real time while taking systemic circulation, metabolism, and absorption into consideration. Predictions of drug behavior and efficacy can be greatly enhanced by using models that can mimic and adjust to the changing biochemical conditions of the human body (Agoram et al., 2001). Furthermore, by using spiking neural networks and bioinspired feedback loops to identify weak or hidden signals that traditional algorithms frequently miss, neuromorphic AI systems have unmatched promise in identifying uncommon or elusive therapeutic targets for neurological illnesses. This self-evolving intelligence highlights the revolutionary role of neuromorphic AI in bringing about a new era of precision pharmacology and cognitively inspired biomedical innovation by opening new avenues for the discovery of novel therapeutic pathways for complex brain-related conditions like Alzheimer's, Parkinson's, and treatment-resistant epilepsy (Khare et al., 2025).

AI in Pharma Blockchain Securing the Drug Pipeline

The pharmaceutical sector is transforming due to the combination of blockchain technology and artificial intelligence (AI), which is turning conventional medication supply chains into decentralized, transparent, and safe networks (Omidian et al., 2024). The development of decentralized AI-led pharmaceutical supply chains, which allow for the monitoring of medications from producer to consumer without the possibility of counterfeiting, is one of the most revolutionary developments in this field. Stakeholders may use real-time data analytics and predictive modeling to identify irregularities, flag questionable transactions, and guarantee product authenticity at every turn by integrating AI algorithms into blockchain networks. Smart contracts, which are autonomous, AI-powered protocols that are maintained on a blockchain, are essential for autonomously enforcing regulatory compliance since they do away with human mistakes and inefficiencies that come with manual monitoring. These smart contracts ensure end-to-end integrity without the need for middleman audits by automatically validating production conditions, shipping procedures, and certification milestones based on regulatory frameworks (Mohamed et al., 2024). Furthermore, to increase openness and confidence, AI-driven cryptographic medication verification methods are currently being used. Health authorities, pharmacies, and even patients may now accurately identify pharmaceutical items thanks to these technologies, which use machine learning to examine encrypted molecular data and unique IDs on the blockchain. When taken as a whole, these developments represent a paradigm shift toward a future in which pharmaceutical logistics are not only more effective but also naturally immune to theft, fraud, and non-compliance, eventually protecting public health in a world market that is becoming more complicated by the day (Haider et al., 2024).

The Dark Side AI-Powered Designer Drug & Biohacking

Artificial intelligence has opened up new and exciting possibilities in the fields of biohacking and pharmacology, but it has also shown a more sinister and dangerous side. The use of AI to produce designer pharmaceuticals at a rate faster than regulatory supervision is one of the most concerning developments. Rogue developers and cyber-pharmacologists can generate novel psychoactive substances (NPS) that circumvent existing drug restrictions while producing strong, frequently harmful effects by utilizing machine learning algorithms and molecular modeling tools. Originally designed for therapeutic discovery, these AI-powered tools are now being used in underground forums and biohacker groups to create "black-market" pharmaceutical substances with minimal human supervision (Albert et al., 2020). Unpredictable and even fatal results can result from the use of open-source code and neural networks in DIY drug synthesis kits, which enable people without formal experience to modify chemical structures. Significant moral and legal quandaries are brought up by the technological empowerment of uncontrolled actors: Should the creation of compounds without clinical evaluation be prohibited by AI systems? What accountability do the platforms and developers that host these technologies have? In addition to endangering public health through unproven chemicals, the combination of AI and biohacking calls into question established frameworks for scientific responsibility, law enforcement, and medical ethics (Bajrektarevic et al., 2024).

AI-Driven Pharmacy in the Space & Lunar Economy

In the developing space and lunar economy, where conventional pharmaceutical methods encounter previously unheard-of difficulties, the incorporation of artificial intelligence (AI) into pharmacy is causing a paradigm change (Elbadawi et al., 2024). By maximizing synthesis routes, adjusting for fluid dynamics anomalies, and guaranteeing precise formulation even in the absence of gravity-dependent mixing, AI-guided pharmaceutical manufacture in microgravity conditions has the potential to completely transform medication production. In closed-loop ecosystems on space stations or in lunar settlements, where efficiency and real-time adaptation are crucial, this becomes even more important. Furthermore, AI-powered space-based pharmacogenomics is opening the door to customized treatment for the particular physiological changes astronauts encounter in space, such as immune dysregulation, muscular atrophy, and altered metabolism. AI can quickly create customized medication regimens to improve therapeutic efficacy and reduce side effects under spaceflight conditions by evaluating enormous databases of genetic, epigenetic, and biometric data (Pavez Loriè et al., 2021). Furthermore, the increased cosmic radiation exposure during interplanetary flight calls for the creation of innovative medication formulations that are stable and efficient in harsh environments. Here, artificial intelligence is essential for identifying radioprotective chemicals, forecasting molecular resilience, and creating formulations with improved pharmacokinetic profiles appropriate for extended missions. All of these developments together represent a revolutionary step toward autonomous, artificial intelligence-powered medical treatment in space, which is consistent with the larger goal of human expansion into uncharted territory (Lacinski et al., 2024).

Table 2

AI-Driven Pharmaceutical Innovations for the Space and Lunar Economy

Category	AI-Guided Pharmaceutical Manufacturing in Microgravity	Space-Based Pharmacogenomics Tailored for Astronauts' Physiology	AI-Enhanced Radiation-Resistant Drug Formulations for Interplanetary Travel	References
Key Focus Area	Precision drug synthesis in orbit using autonomous platforms and minimal raw materials	Personalized medicine based on individual astronaut biometrics and epigenetic shifts	Developing countermeasures to prevent and repair radiation-induced cellular and molecular damage	Pavez Loriè et al., 2021
AI Applications	- AI-based molecular design and reaction optimization- Real-time robotic lab automation in orbit- Predictive modeling of chemical pathways in altered gravity- Adaptive AI systems for real-time monitoring and quality assurance- Self-healing manufacturing protocols	- AI-driven health surveillance systems- Deep learning for detecting health anomalies from spaceflight genomics- AI-based adjustment of pharmacokinetic models in real-time- Personalized drug scheduling using circadian-aware algorithms- Integration with digital twins of astronauts for simulation-based care	- Generative AI for creating novel radioprotectants- Simulation of radiation exposure scenarios using AI-enhanced physics engines- AI-guided nanoencapsulation techniques- Optimizing antioxidant networks using multi-parameter datasets- Machine learning models predicting long-term drug shelf-stability under radiation stress	Azher et al., 2025
Scientific and Technological Challenges	- Stability of chemical reactions and maintaining reaction rates without gravity- Managing reagent flow and waste in zero-gravity settings- Preventing cross-contamination in enclosed biospheres- Energy constraints on manufacturing modules-	Limited datasets from diverse astronaut populations- Complex gene-drug-environment interactions in space- Incomplete knowledge of long-term space-induced physiological shifts- Ethical challenges of health data transmission and AI-based decisions- Space-	Insufficient radiation analogues on Earth for model training- Challenges in accurately modeling radiation-induced biochemical transformations- Need for long-term drug preservation without refrigeration- Interactions between radiation and drug carriers- Variability in biological responses to radioprotectants	Jamal et al., 2025

	Designing scalable and self-sufficient bioreactors	specific machine learning model validation		
Microgravity-Specific Considerations	- Altered surface tension and diffusion rates- Enhanced drug crystallization and novel compound structures- Higher purity in compounds due to minimized convection- Disruption of standard QA/QC protocols- Necessity of full automation and teleoperation capabilities	- Shifts in immune function, muscle metabolism, and gene expression- Microbiome alterations affecting drug metabolism- Enhanced pharmacovigilance due to space-specific side effects- Importance of small-sample inference models- Difficulties in replicating gravity-adapted drug responses	- Radiation-induced pharmacodynamic shifts- Rapid degradation of traditional drugs- In vivo testing limitations in space- Storage container interactions under space conditions- Immune hypersensitivity due to cumulative space stressors	Bento et al., 2012
Expected Benefits for Space Missions	- On-demand drug production reduces dependency on Earth supply- Extended shelf life and minimized drug wastage- Enables long-duration autonomy for lunar and Mars colonies- Resource-efficient chemical engineering workflows- Bio-adaptive manufacturing platforms tailored to mission duration	- Prevents health deterioration due to mismatched treatments- Enhances crew safety and mental resilience- Facilitates precision monitoring and preventive interventions- Personalized wellness plans improve crew productivity- Supports long-term human presence in deep space environments	- Improved survival rates during long interplanetary missions- Minimized need for bulk medication shipments- Paves the way for radiation-tolerant biomaterials- Advances understanding of human biology in extreme environments- Reduces mission risk due to radiation-induced illness	Lewin III et al., 2016
Future Research Directions	- AI-powered orbital pharmaceutical foundries- Integration with lunar ISRU (In Situ Resource Utilization)- Quantum AI for simulating complex biochemical reactions in space- Expansion of AI tools for biomanufacturing feedback loops- Cross-mission interoperability of pharma-AI systems	- Expansion of AI training datasets via wearable and omics tech- Use of federated learning to protect astronaut privacy- AI-augmented exomedicine protocols for long-term missions- Development of self-correcting health platforms- Integration of AR/VR with AI for medical training in space	- Bioinformatics-driven design of universal space-drug libraries- AI-enhanced stability prediction tools for space pharmaceuticals- Smart packaging technologies with embedded AI sensors- Interdisciplinary research on space-radiation biology- Open-access AI models to simulate space pharmacology scenarios	Bhatia et al., 2024

Future Directions

As we look to the future of pharmacy, we see that artificial intelligence is quickly changing the field and guiding it toward previously unheard-of levels of accuracy, customization, and preventative care (Rani et al., 2024). The emergence of AI-augmented pharmacists, whose real-time human-AI collaboration improves prescription, medication interactions, and patient-specific dose optimization, is one of the most significant changes that lie ahead. As intelligent co-pilots, these AI technologies will be seamlessly incorporated into clinical processes to monitor patient data, analyze test findings, and provide evidence-based suggestions, freeing up pharmacists to concentrate more on patient-facing, empathy-driven care. Meanwhile, next-generation drug development will be made possible by the combination of AI with quantum computing, which will allow for atomic-level, hyper-accurate simulations of molecular activity (Shee Weng et al., 2024). This might significantly speed up the process of finding new drug candidates and enable researchers to make remarkably accurate and timely predictions about molecular effectiveness and safety. AI-driven biopharmaceutical customization is another revolutionary development. Here, machine learning algorithms create customized treatments for extremely uncommon genetic illnesses, providing hope to long-underserved patient groups. Additionally, predictive AI models are being created to predict epidemiological patterns, such as the spread of pandemics and the development of bacteria resistant to antibiotics, enabling pharmacists and public health authorities to foresee and take action well in advance of emergencies. When taken as a whole, these developments represent a significant change from reactive to proactive pharmacological treatment, altering the delivery of medicine in the twenty-first century (Golubnitschaja et al., 2016).

Limitations & Challenges

Although the application of artificial intelligence (AI) in pharmacy has great potential, many intricate restrictions and difficulties need to be carefully considered (Kumar et al., 2023). The prevalence of data bias and the related ethical difficulties are among the most urgent problems. Systemic biases based on location, socioeconomic position, gender, or ethnicity may be unintentionally reinforced by AI models trained on historical or non-representative healthcare data. In addition to undermining the equity of AI-driven pharmaceutical decision-making, this may result in uneven treatment access and worse clinical outcomes for underserved groups. Furthermore, the regulatory environment finds it difficult to keep up with the quick changes in technology. Existing legal and ethical frameworks are either antiquated or disjointed, which leads to regulatory bottlenecks that prevent the safe and uniform deployment of AI across healthcare systems, even as its complexity and reach continue to grow. The situation known as "AI hallucinations," in which models confidently produce false or inaccurate medical information, exacerbates these worries. Such false information might have serious repercussions in the pharmacy setting, such as inaccurate prescriptions, unfavorable medication interactions, or jeopardized treatment regimens (Kim et al., 2025). Furthermore, cybersecurity risks are significant as digital health data and AI-generated prescriptions are increasingly vulnerable to manipulation or attack. Patient safety and data privacy are seriously jeopardized by the possibility that malevolent actors would take advantage of AI systems to change doses, reroute medications, or get private patient information. To guarantee that AI is used as a tool for fair, secure, and efficient pharmaceutical treatment, these difficulties highlight the necessity of strong ethical monitoring, open algorithm creation, multidisciplinary cooperation, and flexible regulatory measures (Goktas et al., 2025).

CONCLUSION

In summary, the growing partnership between pharmacy and artificial intelligence (AI) portends a revolutionary period in healthcare, where the combination of pharmacological knowledge and machine learning algorithms has the potential to completely rethink drug development, clinical judgment, and pharmacy practice. AI has unheard-of potential to maximize therapeutic results and operational efficiency throughout pharmaceutical systems, from speeding up the discovery of new compounds to using predictive analytics to customize drug regimens. But as this technological revolution develops, it is crucial to understand that AI is a potent complement to human interaction rather than a substitute for it. The patient-centered care, clinical judgment, and ethical reasoning of pharmacists are essential elements that must continue to be at the core of healthcare delivery. AI should be seen as a cooperative partner that enhances pharmacists' skills by optimizing processes, reducing pharmaceutical mistakes, and facilitating quicker and better-informed decision-making. Going forward, ethical issues, legal ramifications, and technical stability must all be carefully considered when integrating AI into pharmacy. A responsible, sustainable, and human-centered AI-pharmacy ecosystem will be fostered by ensuring data privacy, avoiding algorithmic bias, preserving openness in decision-making processes, and adhering to regulatory compliance. In the end, this mutually beneficial partnership has a lot of potential, but only if it is directed by a framework that values both creativity and honesty.

REFERENCES

Agoram, B., Woltosz, W. S., & Bolger, M. B. (2001). Predicting the impact of physiological and biochemical processes on oral drug bioavailability. *Advanced Drug Delivery Reviews*, *50*, S41-S67. https://doi.org/10.1016/s0169-409x(01)00179-x

Albert, M. J. (2020). *Crisis and Individuation: Mapping and Navigating the Planetary Crisis Convergence* (Doctoral dissertation, Johns Hopkins University).

Allam, H. (2025). Prescribing the future: The role of artificial intelligence in pharmacy. *Information*, *16*(2), 131. https://doi.org/10.3390/info16020131

Aungst, T. D. (2025). Beyond the fill: Navigating pharmacy's technological future in 2050. *Journal of the American Pharmacists Association*, *65*(1), 102285. https://doi.org/10.1016/j.japh.2024.102285

Azher, K., Nazir, A., Farooq, M. U., Haq, M. R. U., Ali, Z., Dalaq, A. S., ... & Khan, S. (2025). Revolutionizing the Future of Smart Materials: A Review of 4D Printing, Design, Optimization, and Machine Learning Integration. *Advanced Materials Technologies*, 2401369.

Badr, N. G., & Khiami, M. (2024). Improving access to prescription-based care through patient-centered smart pharmacy ecosystems. *ITM Web of Conferences*, *62*, 02003. https://doi.org/10.1051/itmconf/20246202003

Bajrektarevic, A. H., & Bogdanova, K. (2024). Biohacking in the European Union. *Geopolitics,* *History, and International Relations*, *16*(2), 40-61. https://doi.org/10.22381/ghir16220242

Barlow, A., Prusak, E. S., Barlow, B., & Nightingale, G. (2021). Interventions to reduce polypharmacy and optimize medication use in older adults with cancer. *Journal of Geriatric Oncology*, *12*(6), 863-871. https://doi.org/10.1016/j.jgo.2020.12.007

Baxter, S. M. (2006). *An Interdisciplinary Analysis of the Ethical, Medical, and Sociocultural Questions Raised by Therapeutic Equivalence* (Doctoral dissertation, Simon Fraser University).

Bento, V. A. F. (2012). *SWORD: An intelligent vibratory wearable device to improve rehabilitation in stroke patients* (Doctoral dissertation, Universidade de Aveiro (Portugal)).

Bettanti, A., Beccari, A. R., & Biccarino, M. (2024). Exploring the future of biopharmaceutical drug discovery: Can advanced AI platforms overcome current challenges? *Discover Artificial Intelligence*, *4*(1), 1-16. https://doi.org/10.1007/s44163-024-00188-3

Bhatia, N., Khan, M. M., & Arora, S. (2024). The role of artificial intelligence in revolutionizing pharmacological research. *Current Pharmacology Reports*, *10*(6), 323-329. https://doi.org/10.1007/s40495-024-00367-x

Bhatt, P., Singh, S., Kumar, V., Nagarajan, K., Mishra, S. K., Kumar Dixit, P., Kumar, V., & Kumar, S. (2024). Artificial intelligence in pharmaceutical industry: Revolutionizing DrugDevelopment and delivery. *Current Artificial Intelligence*, *02*. https://doi.org/10.2174/0129503752250813231124092946

Brett, J. (2018). *Using Pharmaceutical Benefits Scheme claims data to measure the quality use of psychotropic medicines in the Australian population* (Doctoral dissertation, UNSW Sydney).

Cramer, S. C., Sur, M., Dobkin, B. H., O'Brien, C., Sanger, T. D., Trojanowski, J. Q., Rumsey, J. M., Hicks, R., Cameron, J., Chen, D., Chen, W. G., Cohen, L. G., DeCharms, C., Duffy, C. J., Eden, G. F., Fetz, E. E., Filart, R., Freund, M., Grant, S. J., … Vinogradov, S. (2011). Harnessing neuroplasticity for clinical applications. *Brain*, *134*(6), 1591-1609. https://doi.org/10.1093/brain/awr039

Dixit, S., Kumar, A., Srinivasan, K., Vincent, P. M., & Ramu Krishnan, N. (2024). Advancing genome editing with artificial intelligence: Opportunities, challenges, and future directions. *Frontiers in Bioengineering and Biotechnology*, *11*. https://doi.org/10.3389/fbioe.2023.1335901

Ekpan, F. M., Ori, M. O., Samuel, H. S., & Egwuatu, O. P. (2024). The synergy of AI and Drug delivery: A Revolution in Healthcare. *International Journal of Advanced Biological and Biomedical Research*, *12*(1), 45-67.

Elbadawi, M., Li, H., Ghosh, P., Alkahtani, M. E., Lu, B., Basit, A. W., & Gaisford, S. (2024). Cold laser sintering of medicines: Toward carbon neutral pharmaceutical printing. *ACS Sustainable Chemistry & Engineering*, *12*(30), 11155-11166. https://doi.org/10.1021/acssuschemeng.4c01439

Friedmann, T. (1997). Overcoming the obstacles to gene therapy. *Scientific American*, *276*(6), 95-101. https://doi.org/10.1038/scientificamerican0697-95

Ginsburg, G. (2001). Personalized medicine: Revolutionizing drug discovery and patient care. *Trends in Biotechnology*, *19*(12), 491-496. https://doi.org/10.1016/s0167-7799(01)01814-5

Goktas, P., & Grzybowski, A. (2025). Shaping the future of healthcare: Ethical clinical challenges and pathways to trustworthy AI. *Journal of Clinical Medicine*, *14*(5), 1605. https://doi.org/10.3390/jcm14051605

Golubnitschaja, O., Baban, B., Boniolo, G., Wang, W., Bubnov, R., Kapalla, M., Krapfenbauer, K., Mozaffari, M. S., & Costigliola, V. (2016). Medicine in the early twenty-first century: Paradigm and anticipation - EPMA position paper 2016. *EPMA Journal*, *7*(1). https://doi.org/10.1186/s13167-016-0072-4

Gonzalez-Rodriguez, D., & Perez-Carmona, M. (2023). Psychedelics and artificial intelligence: Integrating AI-powered analysis in phenomenological mental health studies. https://doi.org/10.31234/osf.io/9rnj8

Haider, R., Mehdi, A., Zehra, A., Das, G. K., & Ahmed, Z. (2024). Corruption in the pharmaceutical sector diagnosing the challenges. *International Journal of Integrative Sciences*, *3*(3), 237-278. https://doi.org/10.55927/ijis.v3i3.7728

Hamdy, N. M., Basalious, E. B., El-Sisi, M. G., Nasr, M., Kabel, A. M., Nossier, E. S., & Abadi, A. H. (2024). Advancements in current one-size-fits-all therapies compared to future treatment innovations for better improved chemotherapeutic outcomes: A step-toward personalized medicine. *Current Medical Research and Opinion*, *40*(11), 1943-1961. https://doi.org/10.1080/03007995.2024.2416985

Hemati, H., Patrinos, G. P., Aghaei Meybodi, H. R., Sarhangi, N., Larijani, B., Khodayari, N., & Hasanzad, M. (2024). Introduction to the Future of Medicine. In *A Glimpse at Medicine in the Future* (pp. 1-20). Singapore: Springer Nature Singapore.

Jamal, T., Chen, G., Zheng, L., Duan, H., Muddassir, M., Jamal, R., & Khan, N. H. (2025). Innovative food packaging techniques for space exploration: Ensuring safety and sustainability. *Food Engineering Reviews*. https://doi.org/10.1007/s12393-025-09405-w

Johnson, A. E., Ghassemi, M. M., Nemati, S., Niehaus, K. E., Clifton, D., & Clifford, G. D. (2016). Machine learning and decision support in critical care. *Proceedings of the IEEE*, *104*(2), 444-466. https://doi.org/10.1109/jproc.2015.2501978

Kandhare, P., Kurlekar, M., Deshpande, T., & Pawar, A. (2025). A review on revolutionizing healthcare technologies with AI and ML applications in pharmaceutical sciences. *Drugs and Drug Candidates*, *4*(1), 9. https://doi.org/10.3390/ddc4010009

Khare, N., Khare, P., & Priyadarshi, S. (2025). Investigating Neurodegenerative Diseases From Alzheimer's to Parkinson's. In *Advancing Medical Research Through Neuroscience* (pp. 399-436). IGI Global Scientific Publishing.

Kim, Y., Jeong, H., Chen, S., Li, S. S., Lu, M., Alhamoud, K., Mun, J., Grau, C., Jung, M., Gameiro, R. R., Fan, L., Park, E., Lin, T., Yoon, J., Yoon, W., Sap, M., Tsvetkov, Y., Liang, P. P., Xu, X., … Breazeal, C. (2025). Medical hallucination in Foundation models and their impact on healthcare. https://doi.org/10.1101/2025.02.28.25323115

Kumar, K. (2025). Neuromorphic Advancements: Revolutionizing Healthcare Using Images Through Intelligent Computing. In Revolutionizing AI with Brain-Inspired Technology: Neuromorphic Computing (pp. 289-306). IGI Global Scientific Publishing.

Kumar, M., Nguyen, T. P., Kaur, J., Singh, T. G., Soni, D., Singh, R., & Kumar, P. (2023). Opportunities and challenges in application of artificial intelligence in pharmacology. *Pharmacological Reports*, *75*(1), 3-18. https://doi.org/10.1007/s43440-022-00445-1

Lacinski, R. A., Steller, J. G., Anderson, A., & Nelson, A. M. (2024). Harnessing artificial intelligence for medical diagnosis and treatment during space exploration missions.

Lewin, J. J., Choi, E. J., & Ling, G. (2016). Pharmacy on demand: New technologies to enable miniaturized and mobile drug manufacturing. *American Journal of Health-System Pharmacy*, *73*(2), 45-54. https://doi.org/10.2146/ajhp150639

Mariam, Z., Niazi, S. K., & Magoola, M. (2024). Unlocking the future of drug development: Generative AI, digital twins, and beyond. *BioMedInformatics*, *4*(2), 1441-1456. https://doi.org/10.3390/biomedinformatics4020079

Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalhães, P., Schmidt, S., & Vale, N. (2024). Advancing precision medicine: A review of innovative in Silico approaches for drug development, clinical pharmacology and personalized healthcare. *Pharmaceutics*, *16*(3), 332. https://doi.org/10.3390/pharmaceutics16030332

Mohamed, M. (2024). Smart Contracts for and in Food Chain Management: what to consider, adopt, and where to start: A preparatory study focusing on investigating where smart contracts are best suited within the interactions of farmers and processors.

Omidian, H. (2024). Synergizing blockchain and artificial intelligence to enhance healthcare. *Drug Discovery Today*, *29*(9), 104111. https://doi.org/10.1016/j.drudis.2024.104111

Pavez Loriè, E., Baatout, S., Choukér, A., Buchheim, J., Baselet, B., Dello Russo, C., Wotring, V., Monici, M., Morbidelli, L., Gagliardi, D., Stingl, J. C., Surdo, L., & Yip, V. L. (2021). The future of personalized medicine in space: From observations to countermeasures. *Frontiers in Bioengineering and Biotechnology*, *9*. https://doi.org/10.3389/fbioe.2021.739747

Prajapati, R. N., Bhushan, B., Singh, K., Chopra, H., Kumar, S., Agrawal, M., Pathak, D., Chanchal, D. K., & Laxmikant. (2024). Recent advances in pharmaceutical design: Unleashing the potential ofNovel therapeutics. *Current Pharmaceutical Biotechnology*, *25*(16), 2060-2077. https://doi.org/10.2174/0113892010275850240102105033

Rani, S., Kataria, A., Bhambri, P., Pareek, P. K., & Puri, V. (2024). Artificial Intelligence in Personalized Health Services for Better Patient Care. In *Revolutionizing Healthcare: AI Integration with IoT for Enhanced Patient Outcomes* (pp. 89-108). Cham: Springer Nature Switzerland.

Rosendo, L. M., Rosado, T., Zandonai, T., Rincon, K., Peiró, A. M., Barroso, M., & Gallardo, E. (2024). Opioid monitoring in clinical settings: Strategies and implications of tailored approaches for therapy. *International Journal of Molecular Sciences*, *25*(11), 5925. https://doi.org/10.3390/ijms25115925

Sarris, J., Halman, A., Urokohara, A., Lehrner, M., & Perkins, D. (2024). Artificial intelligence and psychedelic medicine. *Annals of the New York Academy of Sciences*. https://doi.org/10.1111/nyas.15229

Shee Weng, L. (2024). Water Resilience in Global Supply Chains: Innovations, Challenges, and Strategic Solutions for Sustainable Resource Management. *Water Resilience in Global Supply Chains: Innovations, Challenges, and Strategic Solutions for Sustainable Resource Management (December 19, 2024)*.

Sobhani, N., D'Angelo, A., Pittacolo, M., Mondani, G., & Generali, D. (2024). Future AI will most likely predict antibody-drug conjugate response in oncology: A review and expert opinion. *Cancers*, *16*(17), 3089. https://doi.org/10.3390/cancers16173089

Tade, R. S., Jain, S. N., Satyavijay, J. T., Shah, P. N., Bari, T. D., Patil, T. M., & Shah, R. P. (2024). Artificial intelligence in the paradigm shift of pharmaceutical sciences: A review. *Nano Biomedicine and Engineering*, *16*(1), 64-77. https://doi.org/10.26599/nbe.2023.9290043

Yadav, S., Singh, A., Singhal, R., & Yadav, J. P. (2024). Revolutionizing drug discovery: The impact of artificial intelligence on advancements in pharmacology and the pharmaceutical industry. *Intelligent Pharmacy*, *2*(3), 367-380. https://doi.org/10.1016/j.ipha.2024.02.009